Get to know our clinical trials
Phase 1, open-label, dose-finding clinical trial of nilk-2401, a bispecific, ceacam5 x cd47 Antibody, as a single agent and in combination with anti-pd-1 Antibody, in patients with ceacam5-expressing solid cancers.
THE AIM OF THIS RESEARCH IS TO EVALUATE WHETHER NILK-2401 AS A SINGLE AGENT HAS BENEFICIAL EFFECTS AND IS SAFE IN PATIENTS WITH THESE CANCERS.
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF NILK-2401, A BISPECIFIC, CEACAM5 X CD47 ANTIBODY, AS A SINGLE AGENT AND IN COMBINATION WITH ANTI-PD-1 ANTIBODY, IN PATIENTS WITH CEACAM5-EXPRESSING SOLID CANCERS.
- Code EudraCT: 2024-512175-12-00
- Protocol number: LCB-2401-001
- Promoter: Light Chain Bioscience; Novimmune S.A.
- Molecule/Drug: NILK-2401
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.